carbapenems has been researched along with mk-7655 in 22 studies
Studies (carbapenems) | Trials (carbapenems) | Recent Studies (post-2010) (carbapenems) | Studies (mk-7655) | Trials (mk-7655) | Recent Studies (post-2010) (mk-7655) |
---|---|---|---|---|---|
7,355 | 147 | 5,277 | 140 | 9 | 136 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 3 (13.64) | 24.3611 |
2020's | 19 (86.36) | 2.80 |
Authors | Studies |
---|---|
Chang, KT; Hirsch, EB; Ledesma, KR; Motyl, MR; Schwartz, MS; Tam, VH | 1 |
Ammerman, NC; Kaushik, A; Kreiswirth, BN; Lamichhane, G; Lee, J; Martins, O; Nuermberger, EL; Parrish, NM | 1 |
Hsu, AJ; Tamma, PD | 1 |
Sfeir, MM | 1 |
Bassetti, M; Battaglini, D; Giacobbe, DR; Pelosi, P; Vena, A | 1 |
Chahine, EB; Karaoui, LR; Mansour, H; Ouweini, AEL | 1 |
Hsieh, YJ; Kao, LT; Lian, SH; Lin, IL; Liu, GH; Lu, PL; Tseng, SP; Wang, HY; Wang, LC; Yang, TY | 1 |
Bragantini, D; Carrara, E; Cattaneo, P; Chiamenti, M; Ellis, S; Franceschi, F; Giske, CG; Lodise, T; Menchinelli, G; Piddock, LJV; Righi, E; Sanguinetti, M; Savoldi, A; Scudeller, L; Tacconelli, E | 1 |
Horwich-Scholefield, S; Huang, S; Lloyd, T; Pandori, M; Varghese, V; Yette, E | 1 |
Arend, LNVS; Bail, L; Ito, CAS; Nogueira, KDS; Tuon, FF | 1 |
Chen, L; Chen, T; Fang, R; Liao, W; Xu, C; Zhang, S; Zhou, C; Zhou, T | 1 |
Lodise, TP; O'Donnell, JN | 1 |
Birgy, A; Bonacorsi, S; Courroux, C; Danjean, M; Gits-Muselli, M; Hobson, CA; Monjault, A | 1 |
Findlay, J; Nordmann, P; Poirel, L; Rens, C | 1 |
Haines, RR; Hammer, KA; Putsathit, P; Tai, AS | 1 |
König, E; Zollner-Schwetz, I | 1 |
Carvalhaes, CG; Castanheira, M; Duncan, L; Kimbrough, JH; Mendes, RE; Sader, HS | 1 |
Gu, Y; Hu, D; Hu, M; Liang, R; Wang, D; Wang, M; Zhu, M | 1 |
DeRyke, CA; Hackel, M; Hilbert, DW; Motyl, M; Young, K | 1 |
Lukovic, B; Petrovic, I; Zornic, S | 1 |
Ahmed, A; Chryssanthou, E; Davies Forsman, L; Fröberg, G | 1 |
Gill, CM; Lee, SY; Nicolau, DP | 1 |
5 review(s) available for carbapenems and mk-7655
Article | Year |
---|---|
Defining the Role of Novel β-Lactam Agents That Target Carbapenem-Resistant Gram-Negative Organisms.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Aztreonam; Boronic Acids; Carbapenems; Cefiderocol; Ceftazidime; Cephalosporins; Cilastatin, Imipenem Drug Combination; Drug Combinations; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Heterocyclic Compounds, 1-Ring; Meropenem; Tazobactam | 2019 |
The role of new antimicrobials for Gram-negative infections in daily clinical practice.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Azabicyclo Compounds; beta-Lactams; Carbapenems; Cefiderocol; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Bacterial; Gram-Negative Bacterial Infections; Humans; Imipenem; Microbial Sensitivity Tests; Polymyxins; Sisomicin; Tazobactam; Tetracyclines | 2020 |
Systematic review and meta-analysis of in vitro efficacy of antibiotic combination therapy against carbapenem-resistant Gram-negative bacilli.
Topics: Amikacin; Anti-Bacterial Agents; Azabicyclo Compounds; Carbapenems; Ceftazidime; Cephalosporins; Colistin; Drug Combinations; Drug Resistance, Bacterial; Drug Synergism; Drug Therapy, Combination; Fosfomycin; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Imipenem; In Vitro Techniques; Microbial Sensitivity Tests; Polymyxins; Rifampin; Tazobactam; Tobramycin | 2021 |
New Perspectives on Antimicrobial Agents: Imipenem-Relebactam.
Topics: Adult; Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; Carbapenems; Humans; Imipenem; Microbial Sensitivity Tests; Pneumonia, Bacterial; Pseudomonas aeruginosa | 2022 |
Treatment options for multidrug-resistant Gram-negatives in urinary tract infections.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; Carbapenems; Gram-Negative Bacterial Infections; Humans; Imipenem; Urinary Tract Infections | 2023 |
17 other study(ies) available for carbapenems and mk-7655
Article | Year |
---|---|
In vitro activity of MK-7655, a novel β-lactamase inhibitor, in combination with imipenem against carbapenem-resistant Gram-negative bacteria.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; Carbapenems; Gram-Negative Bacteria; Imipenem; Klebsiella pneumoniae; Microbial Sensitivity Tests; Models, Theoretical | 2012 |
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; beta-Lactams; Boronic Acids; Carbapenems; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Mycobacterium abscessus; Mycobacterium Infections, Nontuberculous | 2019 |
Imipenem-relebactam for Treatment of Carbapenem-resistant Gram-negative Bacteria: Where Do We Stand on In Vitro Susceptibility Testing?
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Infections; Carbapenems; Colistin; Double-Blind Method; Gram-Negative Bacteria; Humans; Imipenem | 2021 |
Imipenem/cilastatin/relebactam: A new carbapenem β-lactamase inhibitor combination.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Azabicyclo Compounds; Carbapenems; Cilastatin; Cilastatin, Imipenem Drug Combination; Humans; Imipenem; Microbial Sensitivity Tests | 2021 |
Activities of imipenem-relebactam combination against carbapenem-nonsusceptible Enterobacteriaceae in Taiwan.
Topics: Animals; Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Proteins; beta-Lactamases; Caenorhabditis elegans; Carbapenems; Drug Combinations; Drug Resistance, Bacterial; Enterobacteriaceae; Escherichia coli; Humans; Imipenem; Microbial Sensitivity Tests; Taiwan | 2022 |
Imipenem-Relebactam Susceptibility and Genotypic Characteristics of Carbapenem-Resistant
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Proteins; beta-Lactamases; Carbapenems; Drug Resistance, Bacterial; Gammaproteobacteria; Imipenem; Microbial Sensitivity Tests | 2021 |
Activity of imipenem-relebactam and ceftolozane-tazobactam against carbapenem-resistant Pseudomonas aeruginosa and KPC-producing Enterobacterales.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamases; Carbapenems; Cephalosporins; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Enzymologic; Imipenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Tazobactam | 2022 |
In vitro activity of imipenem-relebactam alone and in combination with fosfomycin against carbapenem-resistant gram-negative pathogens.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamases; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Escherichia coli; Fosfomycin; Humans; Imipenem; Klebsiella pneumoniae; Microbial Sensitivity Tests | 2022 |
Evaluation of the inoculum effect of new antibiotics against carbapenem-resistant enterobacterales.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; Carbapenems; Cefiderocol; Humans; Imipenem; Meropenem; Tazobactam | 2022 |
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Ceftazidime; Cephalosporins; Drug Combinations; Escherichia coli; Humans; Imipenem; Klebsiella Infections; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests | 2022 |
Activity of newest generation β-lactam/β-lactamase inhibitor combination therapies against multidrug resistant Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; Carbapenems; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Humans; Imipenem; Lactams; Microbial Sensitivity Tests; Monobactams; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2022 |
Ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam activities against multidrug-resistant Enterobacterales from United States Medical Centers (2018-2022).
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamases; Carbapenems; Ceftazidime; Drug Combinations; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; United States | 2023 |
In vitro activity of ceftazidime/avibactam, imipenem/relebactam and meropenem/vaborbactam alone or in combination with polymyxin B against carbapenem resistant Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; Carbapenems; Ceftazidime; Drug Combinations; Imipenem; Meropenem; Microbial Sensitivity Tests; Polymyxin B | 2023 |
Relebactam restores susceptibility of resistant Pseudomonas aeruginosa and Enterobacterales and enhances imipenem activity against chromosomal AmpC-producing species: analysis of global SMART 2018-2020.
Topics: Anti-Bacterial Agents; Carbapenems; Gammaproteobacteria; Humans; Imipenem; Pseudomonas aeruginosa | 2023 |
In vitro activity of imipenem/relebactam and ceftazidime/avibactam against carbapenem-resistant Klebsiella pneumoniae from blood cultures in a University hospital in Serbia.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Blood Culture; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Ceftazidime; Colistin; Drug Combinations; Hospitals, University; Humans; Imipenem; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Serbia | 2023 |
The
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Drug Combinations; Imipenem; Microbial Sensitivity Tests; Mycobacterium abscessus | 2023 |
Activity of novel β-lactam/β-lactamase inhibitor combinations against serine carbapenemase-producing carbapenem-resistant Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Ceftazidime; Drug Combinations; Imipenem; Lactams; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa | 2023 |